News Daily News Nuevos Roles de las Clínicas Especializadas en Anticoagulación en una Era de Opciones Sin Warfarina Todd Neale March 01, 2016
News Daily News New Roles for Anticoagulation Clinics in an Era of Non-Warfarin Options Todd Neale March 01, 2016
News Conference News ISC 2016 To Anticoagulate or Not? Debating Secondary Stroke Prevention in an A-fib Patient With Microbleeds Michael O'Riordan February 23, 2016
News Daily News Final CMS Decision Memo for Watchman Dumps Controversial Warfarin Contraindication Shelley Wood February 08, 2016
News Daily News In the Real World, Dabigatran and Warfarin Give Equal Stroke Protection to A-fib Patients Todd Neale January 25, 2016
News Daily News Year in Review: Physicians Select the Most Important News of 2015, in Interventional Cardiology and Beyond December 23, 2015
News Daily News Triple Therapy, Especially With Prasugrel, Increases Bleeding Risk in Acute MI Yael L. Maxwell December 22, 2015
News Daily News El Tratamiento Triple, sobre todo con Prasugrel, Aumenta el Riesgo Hemorrágico de los IAM Yael L. Maxwell December 22, 2015
News Daily News Study Affirms Cost-Effectiveness of Watchman LAA Closure Device for Stroke Reduction L.A. McKeown December 14, 2015
News Daily News Case Study Highlights Risks for A-fib Patients Undergoing PCI in Absence of Evidence-Based Guidelines Yael L. Maxwell December 14, 2015
Presentation Time to Cost-Effectiveness After Stroke Reduction Strategies in A-fib: Warfarin vs Novel Oral Anticoagulants (NOACs) vs Left Atrial Appendage (LAA) Closure Presenter: Vivek Y. Reddy December 13, 2015
News Daily News Societies Issue Recommendations for Operators, Institutions Offering LAA Closure Procedures L.A. McKeown December 10, 2015
News Industry News Praxbind® (idarucizumab) approved in European Union for the specific reversal of Pradaxa® (dabigatran etexilate) November 29, 2015
News Conference News AHA 2015 Reversal Agents Safely Stop Effects of Novel Oral Anticoagulants Yael L. Maxwell November 10, 2015
News Conference News AHA 2015 DAPT Score Provides ‘Personalized Medicine’ Tool for Determining Whether to Extend Therapy Beyond 1 Year Yael L. Maxwell November 09, 2015